Research Abstract
My research is centered in the fields of breast and gynecological malignancies. This involves the development of protocols examining the roles of different drugs in the treatment of ovarian, cervical and endometrial cancer.
Susana M. Campos, MD
Dana-Farber Cancer Institute
Dana-Farber Cancer Institute
Phone: (617) 632-5874
Fax: (617) 632-3479
Susana M. Campos, MD
Dana-Farber Cancer Institute
EDUCATIONAL TITLES
DF/HCC PROGRAM AFFILIATION
Publications
- Lee EK, Xiong N, Cheng SC, Barry WT, Penson RT, Konstantinopoulos PA, Hoffman MA, Horowitz N, Dizon DS, Stover EH, Wright AA, Campos SM, Krasner C, Morrissey S, Whalen C, Quinn R, Matulonis UA, Liu JF. Combined pembrolizumab and pegylated liposomal doxorubicin in platinum resistant ovarian cancer: A phase 2 clinical trial. Gynecol Oncol 2020. PubMed
- Arend RC, Beer HM, Cohen YC, Berlin S, Birrer MJ, Campos SM, Rachmilewitz Minei T, Harats D, Wall JA, Foxall ME, Penson RT. Ofranergene obadenovec (VB-111) in platinum-resistant ovarian cancer; favorable response rates in a phase I/II study are associated with an immunotherapeutic effect. Gynecol Oncol 2020; 157:578-584. PubMed
- Abu-Rustum NR, Yashar CM, Bean S, Bradley K, Campos SM, Chon HS, Chu C, Cohn D, Crispens MA, Damast S, Fisher CM, Frederick P, Gaffney DK, Giuntoli R, Han E, Huh WK, Lurain Iii JR, Mariani A, Mutch D, Nagel C, Nekhlyudov L, Fader AN, Remmenga SW, Reynolds RK, Sisodia R, Tillmanns T, Ueda S, Urban R, Wyse E, McMillian NR, Motter AD. NCCN Guidelines Insights: Cervical Cancer, Version 1.2020. J Natl Compr Canc Netw 2020; 18:660-666. PubMed
- Abu-Rustum NR, Yashar CM, Bean S, Bradley K, Campos SM, Chon HS, Chu C, Cohn D, Crispens MA, Damast S, Dorigo O, Eifel PJ, Fisher CM, Frederick P, Gaffney DK, Han E, Huh WK, Lurain JR, Mariani A, Mutch D, Nagel C, Nekhlyudov L, Fader AN, Remmenga SW, Reynolds RK, Sisodia R, Tillmanns T, Ueda S, Wyse E, McMillian NR, Scavone J. Gestational Trophoblastic Neoplasia, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 2019; 17:1374-1391. PubMed
- Veneris JT, Lee EK, Goebel EA, Nucci MR, Lindeman N, Horowitz NS, Lee L, Raut CP, Crotzer D, Matulonis U, Konstantinopoulos PA, Campos S. Diagnosis and management of a recurrent polymerase-epsilon (POLE)-mutated endometrial cancer. Gynecol Oncol 2019. PubMed
- Koh WJ, Abu-Rustum NR, Bean S, Bradley K, Campos SM, Cho KR, Chon HS, Chu C, Clark R, Cohn D, Crispens MA, Damast S, Dorigo O, Eifel PJ, Fisher CM, Frederick P, Gaffney DK, Han E, Huh WK, Lurain JR, Mariani A, Mutch D, Nagel C, Nekhlyudov L, Fader AN, Remmenga SW, Reynolds RK, Tillmanns T, Ueda S, Wyse E, Yashar CM, McMillian NR, Scavone JL. Cervical Cancer, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 2019; 17:64-84. PubMed
- Koh WJ, Abu-Rustum NR, Bean S, Bradley K, Campos SM, Cho KR, Chon HS, Chu C, Cohn D, Crispens MA, Damast S, Dorigo O, Eifel PJ, Fisher CM, Frederick P, Gaffney DK, George S, Han E, Higgins S, Huh WK, Lurain JR, Mariani A, Mutch D, Nagel C, Nekhlyudov L, Fader AN, Remmenga SW, Reynolds RK, Tillmanns T, Ueda S, Wyse E, Yashar CM, McMillian NR, Scavone JL. Uterine Neoplasms, Version 1.2018, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 2018; 16:170-199. PubMed
- Alabed YZ, Cheng SC, Mudge C, Sakellis C, Van den Abbeele AD, Campos SM, Jacene HA. Surveillance Imaging in Patients With Endometrial Cancer in First Remission. 2017. PubMed
- Koh WJ, Greer BE, Abu-Rustum NR, Campos SM, Cho KR, Chon HS, Chu C, Cohn D, Crispens MA, Dizon DS, Dorigo O, Eifel PJ, Fisher CM, Frederick P, Gaffney DK, Han E, Higgins S, Huh WK, Lurain JR, Mariani A, Mutch D, Nagel C, Nekhlyudov L, Fader AN, Remmenga SW, Reynolds RK, Tillmanns T, Ueda S, Valea FA, Wyse E, Yashar CM, McMillian N, Scavone J. Vulvar Cancer, Version 1.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 2017; 15:92-120. PubMed
- Del Carmen MG, Supko JG, Horick NK, Rauh-Hain JA, Clark RM, Campos SM, Krasner CN, Atkinson T, Birrer MJ. Phase 1 and 2 study of carboplatin and pralatrexate in patients with recurrent, platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer. Cancer 2016. PubMed
- Picard M, Pur L, Caiado J, Giavina-Bianchi P, Galvão VR, Berlin ST, Campos SM, Matulonis UA, Castells MC. Risk stratification and skin testing to guide re-exposure in taxane-induced hypersensitivity reactions. J Allergy Clin Immunol 2016; 137:1154-1164.e12. PubMed
- Koh WJ, Greer BE, Abu-Rustum NR, Apte SM, Campos SM, Cho KR, Chu C, Cohn D, Crispens MA, Dorigo O, Eifel PJ, Fisher CM, Frederick P, Gaffney DK, Han E, Huh WK, Lurain JR, Mutch D, Fader AN, Remmenga SW, Reynolds RK, Teng N, Tillmanns T, Valea FA, Yashar CM, McMillian NR, Scavone JL. Cervical Cancer, Version 2.2015. J Natl Compr Canc Netw 2015; 13:395-404; quiz 404. PubMed
- Worley MJ, Davis M, Berhie SH, Muto MG, Feltmate CM, Berkowitz RS, Horowitz NS, Campos SM. Mucinous differentiation does not impact stage or risk of recurrence among patients with grade 1, endometrioid type, endometrial carcinoma. Gynecol Oncol 2014; 135:54-7. PubMed
- Campos SM, Brady WE, Moxley KM, O'Cearbhaill RE, Lee PS, DiSilvestro PA, Rotmensch J, Rose PG, Thaker PH, O'Malley DM, Hanjani P, Zuna RE, Hensley ML. A phase II evaluation of pazopanib in the treatment of recurrent or persistent carcinosarcoma of the uterus: a gynecologic oncology group study. Gynecol Oncol 2014. PubMed
- Koh WJ, Greer BE, Abu-Rustum NR, Apte SM, Campos SM, Chan J, Cho KR, Cohn D, Crispens MA, Dupont N, Eifel PJ, Fader AN, Fisher CM, Gaffney DK, George S, Han E, Huh WK, Lurain JR, Martin L, Mutch D, Remmenga SW, Reynolds RK, Small W, Teng N, Tillmanns T, Valea FA, McMillian N, Hughes M. Uterine neoplasms, version 1.2014. J Natl Compr Canc Netw 2014; 12:248-80. PubMed
- Viswanathan AN, Lee H, Berkowitz R, Berlin S, Campos S, Feltmate C, Horowitz N, Muto M, Sadow CA, Matulonis U. A prospective feasibility study of radiation and concurrent bevacizumab for recurrent endometrial cancer. Gynecol Oncol 2014; 132:55-60. PubMed
- Dizon DS, Ambrosio AJ, Feltmate C, Wright AA, Campos SM, Viswanathan A, . Pushing the bar in treatment of cervical cancer: what can comprehensive cancer centers do on their own? Gynecol Oncol 2013; 131:464-6. PubMed
- Rauh-Hain JA, Nitschmann CC, Worley MJ, Bradford LS, Berkowitz RS, Schorge JO, Campos SM, del Carmen MG, Horowitz NS. Platinum resistance after neoadjuvant chemotherapy compared to primary surgery in patients with advanced epithelial ovarian carcinoma. Gynecol Oncol 2013; 129:63-8. PubMed
- Koh WJ, Greer BE, Abu-Rustum NR, Apte SM, Campos SM, Chan J, Cho KR, Cohn D, Crispens MA, DuPont N, Eifel PJ, Gaffney DK, Giuntoli RL, Han E, Huh WK, Lurain JR, Martin L, Morgan MA, Mutch D, Remmenga SW, Reynolds RK, Small W, Teng N, Tillmanns T, Valea FA, McMillian NR, Hughes M, . Cervical cancer. J Natl Compr Canc Netw 2013; 11:320-43. PubMed
- Campos SM, Penson RT, Matulonis U, Horowitz NS, Whalen C, Pereira L, Tyburski K, Roche M, Szymonifka J, Berlin S. A phase II trial of Sunitinib malate in recurrent and refractory ovarian, fallopian tube and peritoneal carcinoma. Gynecol Oncol 2013. PubMed
- Matulonis UA, Pereira L, Liu J, Lee H, Lee J, Whalen C, Campos S, Atkinson T, Hill M, Berlin S. Sequential bevacizumab and oral cyclophosphamide for recurrent ovarian cancer. Gynecol Oncol 2012; 126:41-6. PubMed
- Campos SM, Berlin S, Matulonis UA, Muto MG, Pereira L, Mosquera MM, Horowitz N. Young women diagnosed with early-stage ovarian cancer or borderline malignancy of the ovary: a focus on fertility and sexual function. J Psychosoc Oncol 2012; 30:387-401. PubMed
- Greer BE, Koh WJ, Abu-Rustum NR, Apte SM, Campos SM, Chan J, Cho KR, Copeland L, Crispens MA, Dupont N, Eifel PJ, Gaffney DK, Huh WK, Kapp DS, Lurain JR, Martin L, Morgan MA, Morgan RJ, Mutch D, Remmenga SW, Reynolds RK, Small W, Teng N, Valea FA. Cervical cancer. J Natl Compr Canc Netw 2010; 8:1388-416. PubMed
- Campos SM, Berlin ST, Parker LM, Chen WY, Bunnell CA, Atkinson T, Lee J, Matulonis U, Hirsch MS, Harris L, Krasner CN. Phase I trial of liposomal doxorubicin and ZD1839 in patients with refractory gynecological malignancies or metastatic breast cancer. Int J Clin Oncol 2010; 15:390-8. PubMed
- Campos SM, Ghosh S. A current review of targeted therapeutics for ovarian cancer. J Oncol 2010; 2010:149362. PubMed
- Penson RT, Dizon DS, Cannistra SA, Roche MR, Krasner CN, Berlin ST, Horowitz NS, Disilvestro PA, Matulonis UA, Lee H, King MA, Campos SM. Phase II study of carboplatin, paclitaxel, and bevacizumab with maintenance bevacizumab as first-line chemotherapy for advanced mullerian tumors. J Clin Oncol 2009; 28:154-9. PubMed
- Matulonis UA, Berlin S, Ivy P, Tyburski K, Krasner C, Zarwan C, Berkenblit A, Campos S, Horowitz N, Cannistra SA, Lee H, Lee J, Roche M, Hill M, Whalen C, Sullivan L, Tran C, Humphreys BD, Penson RT. Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer. J Clin Oncol 2009; 27:5601-6. PubMed
- Mirabeau-Beale KL,Kornblith AB,Penson RT,Lee H,Goodman A,Campos SM,Duska L,Pereira L,Bryan J,Matulonis UA. Comparison of the quality of life of early and advanced stage ovarian cancer survivors. Gynecol Oncol 2009; 114:353-9. PubMed
- Greer BE,Koh WJ,Abu-Rustum N,Bookman MA,Bristow RE,Campos SM,Cho KR,Copeland L,Crispens MA,Eifel PJ,Huh WK,Jaggernauth W,Kapp DS,Kavanagh JJ,Lurain JR 3rd,Morgan M,Morgan RJ,Powell CB,Remmenga SW,Reynolds RK,Alvarez Secord A,Small W Jr,Teng N. NCCN Clinical Practice Guidelines in Oncology: Uterine Neoplasms. J Natl Compr Canc Netw 2009; 7:498-531. PubMed
- Campos SM,Guastalla JP,Subar M,Abreu P,Winer EP,Cameron DA. A comparative study of exemestane versus anastrozole in patients with postmenopausal breast cancer with visceral metastases. Clin Breast Cancer 2009; 9:39-44. PubMed
- Matulonis UA,Horowitz NS,Campos SM,Lee H,Lee J,Krasner CN,Berlin S,Roche MR,Duska LR,Pereira L,Kendall D,Penson RT. Phase II study of carboplatin and pemetrexed for the treatment of platinum-sensitive recurrent ovarian cancer. J Clin Oncol 2008; 26:5761-6. PubMed
- Burstein HJ,Chen YH,Parker LM,Savoie J,Younger J,Kuter I,Ryan PD,Garber JE,Chen H,Campos SM,Shulman LN,Harris LN,Gelman R,Winer EP. VEGF as a marker for outcome among advanced breast cancer patients receiving anti-VEGF therapy with bevacizumab and vinorelbine chemotherapy. Clin Cancer Res 2008; 14:7871-7. PubMed
- Molina FD, Bertollo EM, Assis CM, Falleiros LR Jr, Campos SG, Maniglia JV, Taboga SR. Apoptosis in tongue squamous cell carcinoma and its correlation with clinically occult cervical metastasis. Micron 2008; 39:910-4. PubMed
- Castells MC,Tennant NM,Sloane DE,Hsu FI,Barrett NA,Hong DI,Laidlaw TM,Legere HJ,Nallamshetty SN,Palis RI,Rao JJ,Berlin ST,Campos SM,Matulonis UA. Hypersensitivity reactions to chemotherapy: outcomes and safety of rapid desensitization in 413 cases. J Allergy Clin Immunol 2008; 122:574-80. PubMed
- Campos SG, Zanetoni C, Scarano WR, Vilamaior PS, Taboga SR. Age-related histopathological lesions in the Mongolian gerbil ventral prostate as a good model for studies of spontaneous hormone-related disorders. Int J Exp Pathol 2008; 89:13-24. PubMed
- Partridge EE, Abu-Rustum N, Campos S, Fahey PJ, Greer BE, Lele SM, Lieberman RW, Lipscomb GH, Morgan M, Nava ME, Reynolds RK, Singh DK, Smith-McCune K, Teng N, Trimble CL, Valea F, Wilczynski S, National Comprehensive Cancer Network. Cervical cancer screening. J Natl Compr Canc Netw 2008; 6:58-82. PubMed
- Greer BE, Koh WJ, Abu-Rustum N, Bookman MA, Bristow RE, Campos S, Cho KR, Copeland L, Eifel P, Huh WK, Jaggernauth W, Kapp DS, Kavanagh J, Lipscomb GH, Lurain JR 3rd, Morgan M, Morgan RJ Jr, Powell CB, Remmenga SW, Reynolds RK, Secord AA, Small W Jr, Teng N, National Comprehensive Cancer Network. Cervical cancer. J Natl Compr Canc Netw 2008; 6:14-36. PubMed
- Matulonis UA, Campos S, Krasner CN, Duska LR, Penson RT, Falke R, Roche M, Smith LM, Lee H, Seiden MV, ,. Three sequential chemotherapy doublets for the treatment of newly diagnosed advanced müllerian malignancies: The modified triple doublet regimen. Gynecol Oncol 2006; 103:575-80. PubMed
- Matulonis UA, Campos S, Duska L, Krasner CN, Atkinson T, Penson RT, Seiden MV, Verrill C, Fuller AF, Goodman A,. Phase I/II dose finding study of combination cisplatin and gemcitabine in patients with recurrent cervix cancer. Gynecol Oncol 2006; 103:160-4. PubMed
- Campos S, Seiden MV, Oza A, Plante M, Potkul R, Hamid O, Lenehan P, Kaldjian E, Jordan C, Hirte HA.. A Phase II, randomized, open-label, single agent study of CI-1033 administered at two dose levels in ovarian cancer patients who failed prior platinum based therapy. Proceedings of the American Association of Clinical Oncology 2006.